Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2661-801X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules ; volume:16 ; number:1 ; day:29 ; month:7 ; year:2022 ; pages:1-8 ; date:12.2022
BMC chemistry ; 16, Heft 1 (29.7.2022), 1-8, 12.2022
- Urheber
-
Abdelazim, Ahmed H.
Ramzy, Sherif
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13065-022-00850-w
- URN
-
urn:nbn:de:101:1-2022101513415100634936
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Abdelazim, Ahmed H.
- Ramzy, Sherif
- SpringerLink (Online service)
Ähnliche Objekte (12)
Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms
The First FDA-Approved Antibody-Drug Conjugate
Recently Approved and Upcoming Treatments for Narcolepsy
Spectrophotometric, chromatographic and bioanalysis of selected recently approved drugs from 2015–2020 to treat cardiovascular diseases: an analytical review
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms
The First FDA-Approved Antibody-Drug Conjugate
Recently Approved and Upcoming Treatments for Narcolepsy
Spectrophotometric, chromatographic and bioanalysis of selected recently approved drugs from 2015–2020 to treat cardiovascular diseases: an analytical review
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms
The First FDA-Approved Antibody-Drug Conjugate
Recently Approved and Upcoming Treatments for Narcolepsy
Spectrophotometric, chromatographic and bioanalysis of selected recently approved drugs from 2015–2020 to treat cardiovascular diseases: an analytical review
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia